Reducing the Risk of Cognitive Decline and Dementia: WHO Recommendations

Neerja Chowdhary*, Corrado Barbui, Kaarin J. Anstey, Mariagene Barbera, Ruth Peters, Lidan Zheng, Jenni Kulmala, Ruth Stephen, Cleusa P. Ferri, Yves Joanette, Huali Wang, Charles Alessi, Kusumadewi Suharya (Dy), Miia Kivipelto, Charles A. Hardy, Ronald C. Petersen, Ayesha A. Motala, Shanthi Mendis, Dorairaj Prabhakaran, Ameenah Bibi M. Sorefan, Amit Dias, Riadh Gouider, Suzana Shahar, Kimberly Ashby-Mitchell, Martin Prince and Tarun Dua

With population ageing worldwide, dementia poses one of the greatest global challenges for health and social care in the 21st century. In 2019, around 55 million people were affected by dementia, with the majority living in low- and middle-income countries. Dementia leads to increased costs for governments, communities, families and individuals. Dementia is overwhelming for the family and caregivers of the person with dementia, who are the cornerstone of care and support systems throughout the world. To assist countries in addressing the global burden of dementia, the World Health Organisation (WHO) developed the Global Action Plan on the Public Health Response to Dementia 2017–2025. It proposes actions to be taken by governments, civil society, and other global and regional partners across seven action areas, one of which is dementia risk reduction. This paper is based on WHO Guidelines on risk reduction of cognitive decline and dementia and presents recommendations on evidence-based, multisectoral interventions for reducing dementia risks, considerations for their...
implementation and policy actions. These global evidence-informed recommendations were developed by WHO, following a rigorous guideline development methodology and involved a panel of academicians and clinicians with multidisciplinary expertise and representing geographical diversity. The recommendations are considered under three broad headings: lifestyle and behaviour interventions, interventions for physical health conditions and specific interventions. By supporting health and social care professionals, particularly by improving their capacity to provide gender and culturally appropriate interventions to the general population, the risk of developing dementia can be potentially reduced, or its progression delayed.

**Keywords:** dementia, dementia risk reduction guidelines, dementia risk reduction trials, WHO guidelines, cognitive decline

## INTRODUCTION

With population ageing worldwide, dementia poses one of the greatest global challenges for health and social care in the 21st century. In 2019, around 55 million people were affected by dementia, with the majority living in low- and middle-income countries (LMIC). The total number of people with dementia is projected to reach 78 million in 2030 and 139 million in 2050 (1).

Dementia leads to increased costs for governments, communities, families and individuals. In 2019, the total global societal cost of dementia was estimated to be US$1.3 trillion, equivalent to 1.5% of global gross domestic product (GDP). This number is expected to more than double by 2030, reaching US$2.8 trillion (1).

Dementia can be overwhelming for families and caregivers, who are the cornerstone of care and support systems throughout the world. They are impacted by adverse psychological, physical, social and financial consequences (2). Furthermore, a lack of understanding about dementia leads to stigma and discrimination and people with dementia are frequently denied their human rights in both the community and care homes (3). Left unaddressed, dementia represents a significant barrier to global social and economic development.

Crucially, while chronological age is the strongest known risk factor for cognitive decline and dementia, dementia is not a natural or inevitable consequence of ageing. In fact, several studies have recently linked dementia to a number of potentially modifiable risk factors such as physical inactivity, tobacco use, unhealthy diets, and harmful alcohol use. Certain medical conditions—such as depression, diabetes, hypercholesterolemia, obesity and neurodegenerative diseases—are also associated with an increased risk of dementia (4–6).

The increasing global threat that dementia poses, and the lack of established curative treatment make it important to focus attention on risk reduction. The concept of risk reduction incorporates both the factors that increase the likelihood of cognitive decline and impairment, as well as factors that contribute to neurocognitive resilience. Taken together, these measures can effectively reduce the risk of having to live with dementia and can contribute to diminishing the prevalence of dementia in the population. Additionally, by supporting health and social care professionals, particularly by improving their capacity to provide gender and culturally appropriate interventions to the general population, the risk of developing dementia can be potentially reduced, or its progression delayed.

To assist countries in addressing the global burden of dementia, the World Health Organisation (WHO) developed the Global Action Plan on the Public Health Response to Dementia 2017–2025, endorsed by the World Health Assembly in May 2017. It proposes actions to be taken by governments, civil society, and other global and regional partners across the world. The plan includes seven action areas, one of which is dementia risk reduction. This paper is based on the first WHO Guidelines on risk reduction of cognitive decline and dementia (7), and presents recommendations on evidence-based, multisectoral interventions for reducing dementia risks, considerations for their implementation and further research needs.

## WHO METHODOLOGY FOR THE DEVELOPMENT OF GUIDELINES

The WHO guidelines on risk reduction of cognitive decline and dementia was developed by following a rigorous guideline development methodology that is described in the WHO Handbook for guideline development and uses the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (8, 9). To support the guideline development process, a steering group led by the Department of Mental Health and Substance Use at WHO was established and included representatives from WHO regional offices and relevant WHO departments and programmes. Two additional groups were established: a guideline development group (GDG) and an external review group (ERG). The GDG included a panel of academics and clinicians with multidisciplinary expertise on the conditions covered by the guidelines. The 12 risk factors and interventions presented in the guidelines were selected based on reports from two recent systematic reviews (10, 11) and those summarised in existing WHO guidelines, i.e., the Prevention and control of non-communicable diseases (12) and Integrated care for older people (ICOPE) guidelines (13). The choice of 12 risk factors was determined by their potential to be targeted for prevention of dementia, and/or the delay of the progression of cognitive decline. Existing relevant systematic
reviews were identified for each of the 12 risk factors. The quality of existing reviews was assessed using the assessment of multiple systematic reviews (AMSTAR) checklist. A review of evidence was conducted for interventions related to the 12 risk factors of focus to evaluate their efficacy in reducing risk of cognitive decline and/or dementia for adults with normal cognition or mild cognitive impairment (MCI), and took into consideration the study design—randomised controlled trials (RCT) or observational studies, risk of bias, inconsistency, indirectness, imprecision and risk of reporting bias. Evidence was characterised as either high, moderate, low or very low.

The resulting WHO recommendations targeting nine (of the 12 reviewed) modifiable risk factors are based on evidence from 51 good-quality systematic reviews, including those of observational studies, published in the last 2 years and expanded by up to 5 years, when necessary. Further considerations taken into account included: the balance of benefits and harms of each intervention; values and preferences of the end-user involved; costs and resource use; acceptability of the intervention to health care providers; feasibility of implementation; and impact on equity and human rights. In addition to these systematic reviews, other related guidelines were considered in the development of the recommendations. Some of these are detailed in Box 1.

Taking into account these considerations, recommendations were classified by their strength (strong or conditional). Strong recommendations were issued when the multidisciplinary panel was uncertain about the balance between the desirable and undesirable effects, a conditional recommendation was issued. Strong recommendations imply that most individuals would want the intervention and should receive it, while conditional recommendations imply that different choices may be appropriate for individual patients, and they may require assistance at arriving at management decisions. In some instances, even when the quality of evidence was low or very low, it was agreed that if the recommendation would be of general benefit, and this was seen to outweigh the harms, it may still be rated as strong.

The full evidence profiles underpinning the recommendations are available at the WHO website (https://www.who.int/publications/i/item/risk-reduction-of-cognitive-decline-and-dementia).

**WHO RECOMMENDATIONS ON RISK REDUCTION OF COGNITIVE DECLINE AND DEMENTIA**

The guidelines are primarily intended for health care providers working at a first or second level facility or at district level, including basic outpatient and inpatient services. The health care providers may be doctors, nurses, or other cadres of health workers. In addition, the guidelines have implications for policy makers, and health care planners and program managers at national and international level. It is also crucial for the general population, which is more and more engaged in empowering itself and taking action, to maintain good cognitive health. This is especially true in a context where there has been a proliferation of consumer-directed solutions, many of them digital (app, mHealth), for which there is inadequate guidance offered as to their worth or effectiveness.

The recommendations are considered under three broad headings: lifestyle and behaviour interventions, interventions for physical health conditions and specific interventions (Table 1).

**DISCUSSION**

**Guidelines’ Implementation Considerations**

Many of the interventions included in these guidelines are strongly related to managing risk factors for cardiovascular disease and diabetes. Therefore, the implementation of these recommendations should be combined, whenever possible, with the ongoing prevention programmes to reduce the risk of these conditions in the relevant target populations. For example, non-communicable disease prevention programmes need to include dementia as an integral part of action at global and national levels. Such an approach is particularly interesting as it provides

---

**Box 1 | Related WHO guidelines and tools.**

- **mhGAP Intervention guide for mental, neurological and substance use disorders in non-specialist health settings – version 2.0.** Geneva: WHO; 2016. 173 p. Available from: http://www.who.int/mental_health/mhgap/mhGAP_intervention_guide_02/en/
- **Prevention and control of non-communicable diseases: guidelines for primary health care in low-resource settings.** Geneva: WHO; 2012. 72 p. Available from: http://apps.who.int/iris/bitstream/10665/76173/1/9789241548397_eng.pdf
- **Package of essential non-communicable (PEN) disease interventions for primary health care in low-resource settings.** Geneva: WHO; 2010. 85 p. Available from: https://www.who.int/publications/i/item/who-package-of-essential-noncommunicable-(pen)-disease-interventions-for-primary-health-care
- **Global recommendations on physical activity for health.** Geneva: WHO; 2010. 60 p. Available from: http://www.who.int/dietphysicalactivity/publications/9789241599979/en/
- **Guidelines on Integrated care for older people (ICOPE).** Geneva: WHO; 2017. 60 p. Available from: https://www.who.int/publications/i/item/9789241550109
- **HEARTS Technical package for cardiovascular disease management in primary health care: evidence-based treatment protocols (2018).** https://www.who.int/publications/i/item/HEARTS-technical-package
- **Global age-friendly cities: a guide.** Geneva: WHO; 2007. 82 p. Available from: https://www.who.int/ageing/publications/GLOBAL_age_friendly_cities_Guide_English.pdf
- **Recommendations on healthy diet (2019).** http://www.who.int/en/news-room/fact-sheets/detail/healthy-diet [accessed August 25, 2021].
- **Strengthening health systems for treating tobacco dependence in primary care.** Geneva: WHO; 2013. 78 p. Available from: https://www.who.int/publications/i/item/strengthening-health-systems-for-treating-tobacco-dependence-in-primary-care
- **Framework on integrated people-centred health services.** Geneva: WHO; 2016. 12 p. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA66/A69_39-en.pdf?ua=1
opportunities to develop public health policies that will work in synergy and a single designed intervention has the capacity of impacting risk reduction efforts of more than one disease. Countries should include the recommendations in training and education programmes of healthcare providers, so that these interventions can be provided to all adults in primary health care. An important initiative aimed at leveraging mobile technologies to provide health information to those at risk of developing dementia is WHO’s mDementia programme and its mDementia handbook (14). The handbook provides guidance on how to develop, integrate, implement and evaluate a national mHealth programmes and includes message libraries on dementia risk reduction. A summary of policy measures for effective dementia risk reduction is summarised in Box 2.

The optimal preventive effect may be obtained by addressing several risk factors at the same time. Collaboration among different stakeholders and multidisciplinary approaches will also be needed. Local adaptation is necessary to ensure that the guidelines are appropriate for the local conditions that affect the care of people with cognitive decline and dementia in health facilities and the community.
As countries consider how to implement these guidelines, the budgetary and human resource requirements, and other health systems implications should be analysed to identify what inputs and systems are currently available and what areas require additional investment. These may include training of health workers, supply of medicines and adaptations of health information systems to collect data on service utilisation.

**Limitations of the Process**

While these guidelines used transparent and robust methodologies for evidence synthesis and the development of recommendations according to the WHO Handbook for Guideline Development, the limitations of the guidelines chiefly result from the inadequate evidence available for some of the research questions.

Though the prevalence of dementia is increasing in LMIC, most of the studies were conducted in high-income countries. Much of the evidence came from well-resourced settings, which could potentially impact on generalisability. The relatively short follow-up of most intervention trials limits our ability to judge the potential impact of the intervention on the development of cognitive decline and dementia, both of which have long prodromal periods. Additionally, most studies failed to distinguish between mid-life vs. late life risk factors. For example, the majority of the evidence relating to blood pressure-lowering is drawn from late life samples. However, the epidemiological evidence suggests that the association between high blood pressure and increased risk of cognitive decline or dementia is strongest for high blood pressure experienced in mid-life (e.g., 40–65 years) (15). Few studies distinguish between dementia subtypes (i.e., Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, vascular dementia) with most studies only reporting on all-cause dementia.

Few data were available for interventions targeting some of the modifiable risk factors and reporting outcomes related to dementia or cognitive decline. Therefore, although social isolation, depression and hearing loss were included in the initial scoping, no recommendation could be made relating to these risk factors. However, new evidence is emerging for interventions targeting these risk factors and will be considered when the guidelines are updated.

In instances where the evidence was limited, we took advantage of the GRADE methodology (9, 16), which recognises that, in addition to the evidence base, other aspects that are expected to inform the recommendations. These include consideration of values such as gender equality, equity and the protection of human rights, feasibility, resource use and the knowledge and experience of the Guideline Development Group experts.

These limitations, together with the critical analysis of the evidence collected, which is presented in the current issue in a separate paper (17), emphasise the need for further research to fill key knowledge gaps in ways that can enable improved future guidance.

Major research questions that need to be addressed as a priority are listed in Box 3, and complement the conclusions drawn from the paper published in another issue of this journal (17).

**CONCLUSION**

In this article we propose evidence-based recommendations to reduce the risk of cognitive decline and dementia and will facilitate the implementation of WHO’s Global Action Plan on the Public Health Response to Dementia 2017–2025, specifically to achieve the global target for dementia risk reduction.

The recommendations are designed to inform policymakers, healthcare providers, as well as other stakeholders. Given that the risk factors identified by the studies and recommendations proposed in the guidelines are shared among other diseases,
especially with cardiovascular diseases and diabetes, it is of particular importance to identify how to strategically develop interventions and/or integrate such recommendations in a manner that will maximise the impact and increase their cost efficiency.

New evidence in these areas are regularly monitored by WHO, in consultation with international experts and academic partners. These guidelines will be reviewed in around 5 years, unless an earlier review and update is warranted by breakthrough research. We also expect revisions to include relevant new questions or areas currently not covered by these guidelines.

We intend that the publication of the WHO guidelines, and the evidence-base that underpins them, will stimulate interest in the global scientific, policy and practitioner communities and thereby contribute to increase research capacity and strengthen evidence from countries/regions where needed. Though comprehensive and quality evidence has been gathered in the last decade on risk factors for dementia and cognitive decline, efforts should be targeted at improving the representation of LMICs. To achieve that, global prioritisation and coordination are necessary to ensure that ongoing dementia research covers critical areas within dementia risk reduction in ways that harmonise investigative approaches and reduce redundancies. Moreover, research efforts must be rooted in equity, diversity, and inclusiveness, be person-centred and family inclusive. This also necessitates building greater research capacity in all income settings and coordinated actions at the global level with all stakeholders.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

REFERENCES

1. World Health Organization. Global status report on the public health response to dementia 2017-2025. Geneva: World Health Organization. (2021) p. 27. Available online at: https://apps.who.int/iris/bitstream/handle/10665/259615/9789241513487-eng.pdf?sequence=1
2. Alzheimer’s Disease International publication team. From plan to impact: progress towards targets of the Global action plan on dementia. London: Alzheimer’s Disease International. (2018) p. 44. Available online at: https://www.alz.co.uk/adi/pdf/from-plan-to-impact-2018.pdf
3. Lynch C. World Alzheimer Report 2019: Attitudes to dementia, a global survey. Alzheimers Dement. (2020) 16:S10. doi: 10.1002/alz.038255
4. National Institute for Health and Care Excellence. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (2015). Available online at: https://www.nice.org.uk/guidance/ng16 (accessed August 25, 2021).
5. Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer Report 2014: dementia and risk reduction: an analysis of protective and modifiable risk factors. London: Alzheimer's Disease International. (2014) p. 104. Available online at: https://www.alzint.org/u/WorldAlzheimerReport2014.pdf
6. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. (2020) 396:10248. doi: 10.1016/S0140-6736(20)30367-6
7. World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines. Geneva: World Health Organization. (2019) p. 96. Available online at: https://www.who.int/publications/i/item/risk-reduction-of-cognitive-decline-and-dementia
8. World Health Organization. WHO Handbook for Guideline Development, 2nd Edition. Geneva: World Health Organization. (2014). p 179. Available online at: https://www.who.int/publications/i/item/9789241548960
9. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. (2011) 64:4. doi: 10.1016/J.CLINEPID.2010.04.026
10. Livingston G, Sommerlad A, Orgeta V, CostaFreda SG, Huntley J, Ames D et al. Dementia prevention, intervention, and care. Lancet. (2017) 390:10113. doi: 10.1016/S0140-6736(17)31363-6
11. Kane RL, Butler M, Fink HA, Brasure M, Davila H, Desai P et al. Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer’s-type dementia [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US). (2017) p. 693.

AUTHOR CONTRIBUTIONS

TD and NC contribute to overall coordination of the guideline development. NC wrote the first draft of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING

KA is funded by NHMRC Fellowship 1102694. RP and LZ are funded by the NHMRC Dementia Centre for Research Collaboration. LZ is also funded by NHMRC Grant 1100579. MK is funded by Academy of Finland [Grants Nos. 317465 and 335524], the European Union Joint Programme – Neurodegenerative Disease (JPND) project EURO-FINGERS [Academy of Finland Grant No. 334804], Stiftelsen Stockholms Sjukhem, Center for Innovative Medicine (CIMED) at Karolinska Institutet, Knut and Alice Wallenberg Foundation, the Swedish Research Council for Health, Working Life and Welfare, Region Stockholm grants (ALF, NSV), and Konung Gustaf V:s och Drottnings Victoria’s Frimurarstiftelse. AB and MB are funded by the European Research Council (ERC) [Grant No. 804371]. AB and RS are funded by the Finnish Cultural Foundatio. AB is also funded by the Academy of Finland [Grants Nos. 287490 and 319318] and Alzheimerfonden.

ACKNOWLEDGMENTS

The authors thank members of the Guideline Steering Group and the Expert review Group for their contribution in the development of the WHO Guidelines on Risk reduction of cognitive decline and dementia. We are also grateful for the funds received from Public Health England, United Kingdom; Centre for Disease Control and Prevention, United States of America to support the guideline development.
Available online at: https://www.ncbi.nlm.nih.gov/books/NBK442425/pdf/Bookshelf_NBK442425.pdf

12. World Health Organization. Package of essential non-communicable (PEN) disease interventions for primary health care in low-resource settings. Geneva: World Health Organization. (2010)p. 66. Available online at: https://www.who.int/nmh/publications/essential_ncd_interventions_lr_settings.pdf

13. World Health Organization. Integrated care for older people: guidelines on community-level interventions to manage declines in intrinsic capacity. Geneva: World Health Organization. (2017).

14. Be He@lthy, Be Mobile: a handbook on how to implement mDementia. Geneva: World Health Organization and International Telecommunication Union. (2021).

15. Kivipelto M, Heikala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ. (2001) 322:7300. doi: 10.1136/bmj.322.7300.1447

16. Barbui C, Dua T, van Ommeren M, Yasamy MT, Fleischmann A, Clark N et al. Challenges in developing evidence-based recommendations using the grade approach: the case of mental, neurological, and substance use disorders. PLoS Med. (2010) 7:8. doi: 10.1371/journal.pmed.1000322

17. Stephen R, Barbera M, Peters R, Ee N, et al. Development of the first WHO guidelines for risk reduction of cognitive decline and dementia: lessons learned and future directions. Front Neurol. (2021) 12:1896. doi: 10.3389/fneur.2021.763573

Author Disclaimer: The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chowdhary, Barbui, Anstey, Kivipelto, Barbera, Peters, Zheng, Kulmala, Stephen, Ferri, Joanette, Wang, Comas-Herrera, Alessi, Sabarya (Dy), Mwangi, Petersen, Motala, Mendis, Prabhakaran, Bibi Mia Sorefan, Dias, Gouider, Shahar, Ashby-Mitchell, Prince and Dua. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.